抄録
Plasma concentrations of apolipoproteins (apo) A-I, A-II and B in the 52 noninsulin-dependent (type II) diabetics were measured. The diabetics consisted of 35 patients treated with insulin (insulin group), 10 patients treated with oral hypoglycemic agents (mostly glibenclamide: oral drug group), 3 patients on dietary treatment alone (diet group) and 4 untreated patients. Mean (±SE) age were 60.4±13.8, 65.9±11.4, 58.3±9.6 and 65.3±11.2 in insulin group, oral drug group, diet group and untreated diabetics, respectively. Fasting blood glucose levels and HbA1 levels in parenthesis were 158.5±67.3mg/dl (10.5±2.0%), 116.3±23.5mg/dl (9.3±0.6%), 144.5±64.3mg/dl (10.0±6.1%) and 170±54.5mg/dl (10.7±0.5%) in insulin group, oral drug group, diet group, and untreated diabetics, respectively. HDL was fractionated by the method of heparin-MnCl2 precipitation. Plasma apo A-I, A-II and B were measured by single radial immunodiffusion using the commercially available plate. Plasma triglycerides were significantly higher in insulin group (163.1±23.5mg/dl) and oral drug group (171.4±29.9mg/dl) than control (106.5±5.3mg/dl). HDL-C was significantly lower in insulin group (46.5±1.9mg/dl) than control (55.8±1.4mg/dl). Plasma apo B concetrations were significantly increased in the diabetics (insulin group: 104.3±4.5mg/dl, oral drug group: 117.0±8.5mg/dl, diet group: 116.0±8.9mg/dl vs. control group: 91.3±2.8mg/dl). Plasma apo A-I were significantly lower in insulin group (94.8±2.9mg/dl), oral drug group (111.4±6.0mg/dl) than control (126.3±2.9mg/dl). Plasma apo A-II also decreased significantly in insulin group (22.0±0.8mg/dl) and oral drug group (24.6±2.3mg/dl) as compared to control (31.3±0.7mg/dl). Therefore, apo B/apo A-I+apo A-II were significantly increased in insulin group (0.92±0.05mg/dl) and oral drug group (0.94±0.09mg/dl) compared to control (0.59±0.22mg/dl). Apo A-I showed a positive correlation to HDL-C. The present study suggested the usefulness of plasma apo A-I, A-II and B measurement for understanding the derangement of lipoprotein metabolism in the diabetics.
